Strategies to Prevent EBV Reactivation and Posttransplant Lymphoproliferative Disorders (PTLD) after Allogeneic Stem Cell Transplantation in High-Risk Patients

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 5, 2011, Pages 591-597

  Reddy, Nishitha ^a   Rezvani, Katayoun ^b   Barrett, A John ^c   Savani, Bipin N ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

EBV reactivation; Long term survivors; PTLD; Rituximab; Sirolimus; Stem cell transplantation

Indexed keywords

ALEMTUZUMAB; ANTIVIRUS AGENT; CD3 ANTIBODY; CYCLOPHOSPHAMIDE; FLUDARABINE; IMMUNOGLOBULIN; MEPREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; AUTOLOGOUS BONE MARROW TRANSPLANTATION; B LYMPHOCYTE; CHEMOTHERAPY; CLINICAL FEATURE; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS INFECTION; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; IN SITU HYBRIDIZATION; LOW DRUG DOSE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POLYMERASE CHAIN REACTION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PREVALENCE; REVIEW; T CELL DEPLETION; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; LYMPHOPROLIFERATIVE DISORDERS; RISK; SIROLIMUS; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD; VIRUS ACTIVATION;

EID: 79954600403     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.08.007     Document Type: Review

References (80)

1. Styczynski J., Einsele H., Gil L., Ljungman P. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009, 11:383-392.
2. Meijer E., Slaper-Cortenbach I.C., Thijsen S.F., Dekker A.W., Verdonck L.F. Increased incidence of EBV-associated lymphoproliferative disorders after allogeneic stem cell transplantation from matched unrelated donors because of a change of T cell depletion technique. Bone Marrow Transplant 2002, 29:335-339.
3. Landgren O., Gilbert E.S., Rizzo J.D., et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009, 113:4992-5001.
4. Gross T.G., Hinrichs S.H., Davis J.R., et al. Depletion of EBV-infected cells in donor marrow by counterflow elutriation. Exp Hematol 1998, 26:395-399.
5. Lucas K.G., Small T.N., Heller G., Dupont B., O'Reilly R.J. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 1996, 87:2594-2603.
6. Curtis R.E., Travis L.B., Rowlings P.A., et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999, 94:2208-2216.
7. Zutter M.M., Durnam D.M., Hackman R.C., et al. Secondary T-cell lymphoproliferation after marrow transplantation. Am J Clin Pathol 1990, 94:714-721.
8. Trimble M.S., Waye J.S., Walker I.R., Brain M.C., Leber B.F. B-cell lymphoma of recipient origin 9 years after allogeneic bone marrow transplantation for T-cell acute lymphoblastic leukaemia. Br J Haematol 1993, 85:99-102.
9. Leblond V., Davi F., Charlotte F., et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?. J Clin Oncol 1998, 16:2052-2059.
10. Biggar R.J., Jaffe E.S., Goedert J.J., et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006, 108:3786-3791.
11. Gross T.G., Steinbuch M., DeFor T., et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 1999, 23:251-258.
12. Ho A.Y., Adams S., Shaikh H., et al. Fatal donor-derived Epstein-Barr virus-associated post-transplant lymphoproliferative disorder following reduced intensity volunteer-unrelated bone marrow transplant for myelodysplastic syndrome. Bone Marrow Transplant 2002, 29:867-869.
13. Ocheni S., Kroeger N., Zabelina T., et al. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant 2008, 42:181-186.
14. Abruzzo L.V., Rosales C.M., Medeiros L.J., et al. Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol 2002, 26:630-636.
15. Barker J.N., Martin P.L., Coad J.E., et al. Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. Biol Blood Marrow Transplant 2001, 7:395-399.
16. Blaes A.H., Cao Q., Wagner J.E., et al. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. Biol Blood Marrow Transplant 2010, 16:287-291.
17. Heslop H.E. How I treat EBV lymphoproliferation. Blood 2009, 114:4002-4008.
18. Hislop A.D., Annels N.E., Gudgeon N.H., Leese A.M., Rickinson A.B. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med 2002, 195:893-905.
19. Jones K., Nourse J.P., Morrison L., et al. Expansion of EBNA1-specific effector T cells in post-transplant lymphoproliferative disorders. Blood 2010.
20. Meij P., van Esser J.W., Niesters H.G., et al. Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003, 101:4290-4297.
21. Piriou E., van D.K., Nanlohy N.M., et al. Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma. Blood 2005, 106:3166-3174.
22. Munz C., Bickham K.L., Subklewe M., et al. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med 2000, 191:1649-1660.
23. Powell J.L., Bunin N.J., Callahan C., et al. An unexpectedly high incidence of Epstein-Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma. Bone Marrow Transplant 2004, 33:651-657.
24. Anderson K.C., Soiffer R., DeLage R., et al. T-cell-depleted autologous bone marrow transplantation therapy: analysis of immune deficiency and late complications. Blood 1990, 76:235-244.
25. Lones M.A., Kirov I., Said J.W., Shintaku I.P., Neudorf S. Post-transplant lymphoproliferative disorder after autologous peripheral stem cell transplantation in a pediatric patient. Bone Marrow Transplant 2000, 26:1021-1024.
26. Nash R.A., Dansey R., Storek J., et al. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant 2003, 9:583-591.
27. Swerdlow S.H., Webber S.A., Chadburn A., Ferry J. Post transplant lymphoproliferative disorders. Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, 342-349. International Agency for Research on Cancer, Lyon, France. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
28. Annels N.E., Kalpoe J.S., Bredius R.G., et al. Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution. Clin Infect Dis 2006, 42:1743-1748.
29. Rooney C.M., Loftin S.K., Holladay M.S., et al. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 1995, 89:98-103.
30. van Esser J.W., van der H.B., Meijer E., et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001, 98:972-978.
31. Styczynski J., Reusser P., Einsele H., et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009, 43:757-770.
32. Wagner H.J., Cheng Y.C., Huls M.H., et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004, 103:3979-3981.
33. Schonberger S., Meisel R., Adams O., et al. Prospective, comprehensive and effective viral monitoring in children undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010.
34. Gratwohl A., Baldomero H., Aljurf M., et al. Hematopoietic stem cell transplantation: a global perspective. JAMA 2010, 303:1617-1624.
35. Schriber J.R., Anasetti C., Heslop H.E., Leahigh A.K. Preparing for growth: current capacity and challenges in hematopoietic stem cell transplantation programs. Biol Blood Marrow Transplant 2010, 16:595-597.
36. Ballen K.K., King R.J., Chitphakdithai P., et al. The national marrow donor program 20 years of unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008, 14:2-7.
37. Karanes C., Nelson G.O., Chitphakdithai P., et al. Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant 2008, 14:8-15.
38. Wagner J.E., Gluckman E. Umbilical cord blood transplantation: the first 20 years. Semin Hematol 2010, 47:3-12.
39. Barrett A.J., Savani B.N. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006, 20:1661-1672.
40. Brunstein C.G., Laughlin M.J. Extending cord blood transplant to adults: dealing with problems and results overall. Semin Hematol 2010, 47:86-96.
41. Cesaro S., Pegoraro A., Tridello G., et al. A prospective study on modulation of immunosuppression for Epstein-Barr virus reactivation in pediatric patients who underwent unrelated hematopoietic stem-cell transplantation. Transplantation 2010, 89:1533-1540.
42. Heslop H.E., Rooney C.M. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev 1997, 157:217-222.
43. Hartwig U.F., Nonn M., Khan S., et al. Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity. Biol Blood Marrow Transplant 2008, 14:99-109.
44. Heslop H.E., Bollard C.M., Gottschalk S., et al. Immune therapy for EBV infections after hemopoietic stem-cell transplant. Cytotherapy 2002, 4:433-434.
45. Moss D.J., Khanna R., Gandhi M. The use of T-cell directed cellular therapies in Australia. Cytotherapy 2007, 9:222-224.
46. Wagner H.J., Rooney C.M., Heslop H.E. Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002, 8:1-8.
47. Moosmann A., Bigalke I., Tischer J., et al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 2010, 115:2960-2970.
48. Merlo A., Turrini R., Bobisse S., et al. Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors. J Immunol 2010, 184:5895-5902.
49. Gottschalk S., Heslop H.E., Rooney C.M. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma 2005, 46:1-10.
50. Wagner H.J., Sili U., Gahn B., et al. Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15. Cytotherapy 2003, 5:231-240.
51. Rooney C.M., Smith C.A., Ng C.Y., et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998, 92:1549-1555.
52. Heslop H.E., Slobod K.S., Pule M.A., et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010, 115:925-935.
53. Uhlin M., Okas M., Gertow J., et al. A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation. Cancer Immunol Immunother 2010, 59:473-477.
54. Haque T., Wilkie G.M., Jones M.M., et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007, 110:1123-1131.
55. Kuehnle I., Huls M.H., Liu Z., et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000, 95:1502-1505.
56. van Esser J.W., Niesters H.G., van der H.B., et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002, 99:4364-4369.
57. Choquet S., Leblond V., Herbrecht R., et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006, 107:3053-3057.
58. Arai S., Sahaf B., Jones C., et al. 283: Rituximab infusion two months after total lymphoid irradiation-antithymocyte globulin (TLI-ATG) nonmyeloablative transplantation maintains B-cell disease control with minimal GVHD. Biol Blood Marrow Transplant 2007, 13:103.
59. Sahaf B., Chen G., Boiko J., et al. 391: Rituximab infusion after allogeneic HCT prevents donor B cell reconstitution and alloimmunity one year post transplant. Biol Blood Marrow Transplant 2008, 14:142.
60. Savoldo B., Rooney C.M., Quiros-Tejeira R.E., et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant 2005, 5:566-572.
61. Darenkov I.A., Marcarelli M.A., Basadonna G.P., et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997, 64:848-852.
62. Kinch A., Oberg G., Arvidson J., et al. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Scand J Infect Dis 2007, 39:235-244.
63. Sundin M., Le B.K., Ringden O., et al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica 2006, 91:1059-1067.
64. Lowe T., Bhatia S., Somlo G. Second malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007, 13:1121-1134.
65. Nishio M., Fujimoto K., Yamamoto S., et al. Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma. Eur J Haematol 2006, 77:226-232.
66. Savani B.N., Pohlmann P.R., Jagasia M., et al. Does peritransplantation use of rituximab reduce the risk of EBV reactivation and PTLPD?. Blood 2009, 113:6263-6264.
67. Bacigalupo A., Locatelli F., Lanino E., et al. Fludarabine, Cyclophosphamide with or without low dose TBI for alternative donor transplants in acquired aplastic anemia (SAA): a report from the EBMT-SAA Working Party. Biol Blood Marrow Transplant 2009, 15:5.
68. Vianna R.M., Mangus R.S., Fridell J.A., et al. Induction immunosuppression with thymoglobulin and rituximab in intestinal and multivisceral transplantation. Transplantation 2008, 85:1290-1293.
69. Aue G., Lindorfer M.A., Beum P.V., et al. Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. Haematologica 2010, 95:329-332.
70. Khouri I.F., McLaughlin P., Saliba R.M., et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008, 111:5530-5536.
71. Alousi A.M., Uberti J., Ratanatharathorn V. The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant. Leuk Lymphoma 2010, 51:376-389.
72. Kharfan-Dabaja M.A., Bazarbachi A. Emerging role of CD20 blockade in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010.
73. Krams S.M., Martinez O.M. Epstein-Barr virus, rapamycin, and host immune responses. Curr Opin Organ Transplant 2008, 13:563-568.
74. Majewski M., Korecka M., Kossev P., et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA 2000, 97:4285-4290.
75. Muthukkumar S., Ramesh T.M., Bondada S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation 1995, 60:264-270.
76. Armand P., Gannamaneni S., Kim H.T., et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol 2008, 26:5767-5774.
77. Garcia V.D., Bonamigo Filho J.L., Neumann J., et al. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment. Transpl Int 2003, 16:202-206.
78. Matthews K., Gossett J., Kappelle P.V., Jellen G., Pahl E. Indications, tolerance and complications of a sirolimus and calcineurin inhibitor immunosuppression regimen: intermediate experience in pediatric heart transplantation recipients. Pediatr Transplant 2010.
79. Gibelli N.E., Tannuri U., Pinho-Apezzato M.L., et al. Sirolimus in pediatric liver transplantation: a single-center experience. Transplant Proc 2009, 41:901-903.
80. Pulsipher M.A., Wall D.A., Grimley M., et al. A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). Br J Haematol 2009, 147:691-699.